MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319845 | Name: Tedizolid
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tedizolid (also known as TR-700, DA-7157, and Torezolid) is an oxazolidinone-class antibiotic. Tedizolid has been approved by FDA on June 20, 2014, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Tedizolid exerts its bacteriostatic microbial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of the bacteria.

Chemical Structure

Tedizolid
Tedizolid
CAS#856866-72-3

Theoretical Analysis

MedKoo Cat#: 319845

Name: Tedizolid

CAS#: 856866-72-3

Chemical Formula: C17H15FN6O3

Exact Mass: 370.1190

Molecular Weight: 370.34

Elemental Analysis: C, 55.13; H, 4.08; F, 5.13; N, 22.69; O, 12.96

Price and Availability

Size Price Availability Quantity
50mg USD 90.00 Ready to ship
100mg USD 150.00 Ready to ship
500mg USD 250.00 Ready to ship
1g USD 450.00 Ready to ship
2g USD 750.00 Ready to Ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
856867-39-5 (disodium) 856867-55-5 (phosphate) 856866-72-3
Synonym
TR-700; TR 700; TR700; DA-7157; DA7157; DA 7157; Tedizolid; Torezolid; Sivextro
IUPAC/Chemical Name
(5R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one
InChi Key
XFALPSLJIHVRKE-GFCCVEGCSA-N
InChi Code
InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1
SMILES Code
O=C1O[C@@H](CO)CN1C2=CC=C(C3=CC=C(C4=NN(C)N=N4)N=C3)C(F)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#A24M03B16
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Tedizolid acts through the inhibition of bacterial protein synthesis by binding to 23S rRNA of the 50S subunit of the ribosome.
In vitro activity:
Tedizolid has potential in short-course anti-Mycobacterium avium complex (MAC) chemotherapy. in the hollow-fibre system model of intracellular MAC (HFS-MAC), Tedizolid achieved the feat of 2.0 log10 cfu/mL kill below initial bacterial burden, an effect not seen before in this model with other antibiotics. The tedizolid exposure associated with 1.0 log10 cfu/mL kill was a non-protein bound AUC0-24/MIC ratio of 23.46, while that associated with 2.0 log10 cfu/mL kill was 37.50, and the EC80 was 21.71. Reference: J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i30-i35. https://pubmed.ncbi.nlm.nih.gov/28922807/
In vivo activity:
This study investigated the anti-inflammatory effect of Tedizolid using a carrageenan-induced rat footpad edema model. Tedizolid suppresses carrageenan-induced footpad edema and that Tedizolid exerts its anti-inflammatory effects in a plasma concentration-dependent manner. Reference: J Infect Chemother. 2023 Nov;29(11):1088-1090. https://pubmed.ncbi.nlm.nih.gov/37453465/
Solvent mg/mL mM
Solubility
DMSO 10.0 27.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 370.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Toyokawa M, Ohana N, Tanno D, Imai M, Takano Y, Ohashi K, Yamashita T, Saito K, Takahashi H, Shimura H. In vitro activity of tedizolid against 43 species of Nocardia species. Sci Rep. 2024 Mar 4;14(1):5342. doi: 10.1038/s41598-024-55916-7. PMID: 38438563; PMCID: PMC10912709. 2. Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i30-i35. doi: 10.1093/jac/dkx305. PMID: 28922807. 3. Isobe N, Chuang VTG, Liu X, Enoki Y, Taguchi K, Matsumoto K. The anti-inflammatory effect of tedizolid on carrageenan-induced footpad edema rat model. J Infect Chemother. 2023 Nov;29(11):1088-1090. doi: 10.1016/j.jiac.2023.07.007. Epub 2023 Jul 14. PMID: 37453465. 4. Liu X, Tashiro S, Igarashi Y, Takemura W, Kojima N, Morita T, Hayashi M, Enoki Y, Taguchi K, Matsumoto K. Differences in Pharmacokinetic/Pharmacodynamic Parameters of Tedizolid Against VRE and MRSA. Pharm Res. 2023 Jan;40(1):187-196. doi: 10.1007/s11095-022-03425-5. Epub 2022 Nov 3. PMID: 36329373.
In vitro protocol:
1. Toyokawa M, Ohana N, Tanno D, Imai M, Takano Y, Ohashi K, Yamashita T, Saito K, Takahashi H, Shimura H. In vitro activity of tedizolid against 43 species of Nocardia species. Sci Rep. 2024 Mar 4;14(1):5342. doi: 10.1038/s41598-024-55916-7. PMID: 38438563; PMCID: PMC10912709. 2. Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i30-i35. doi: 10.1093/jac/dkx305. PMID: 28922807.
In vivo protocol:
1. Isobe N, Chuang VTG, Liu X, Enoki Y, Taguchi K, Matsumoto K. The anti-inflammatory effect of tedizolid on carrageenan-induced footpad edema rat model. J Infect Chemother. 2023 Nov;29(11):1088-1090. doi: 10.1016/j.jiac.2023.07.007. Epub 2023 Jul 14. PMID: 37453465. 2. Liu X, Tashiro S, Igarashi Y, Takemura W, Kojima N, Morita T, Hayashi M, Enoki Y, Taguchi K, Matsumoto K. Differences in Pharmacokinetic/Pharmacodynamic Parameters of Tedizolid Against VRE and MRSA. Pharm Res. 2023 Jan;40(1):187-196. doi: 10.1007/s11095-022-03425-5. Epub 2022 Nov 3. PMID: 36329373.
1: Liu X, Enoki Y, Taguchi K, Matsumoto K. Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis. J Pharm Pharmacol. 2024 Nov 6:rgae124. doi: 10.1093/jpp/rgae124. Epub ahead of print. PMID: 39504578. 2: Liu Q, He D, Wang L, Wu Y, Liu X, Yang Y, Chen Z, Dong Z, Luo Y, Song Y. Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis. Antibiotics (Basel). 2024 Sep 10;13(9):866. doi: 10.3390/antibiotics13090866. PMID: 39335039; PMCID: PMC11428633. 3: Coustilleres F, Thillard EM, Khanna RK, Olivereau S, Ouaissi M, Pansu N, Le Lez ML. Severe Optic Neuropathy Induced by Very Prolonged Tedizolid as Suppressive Therapy: Description of a Case Report and Implication for Better Assessment. Open Forum Infect Dis. 2024 Sep 24;11(9):ofae517. doi: 10.1093/ofid/ofae517. PMID: 39329109; PMCID: PMC11425497. 4: Milosevic TV, Vertenoeil G, Vainchenker W, Tulkens PM, Constantinescu SN, Van Bambeke F. Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0053324. doi: 10.1128/aac.00533-24. Epub 2024 Sep 19. PMID: 39297641; PMCID: PMC11460550. 5: Gültekin HE, Aydın HH, Şahiner A, Soylu FE, Şenyiğit Z, Karayıldırım ÇK. In vitro and in vivo evaluation of tedizolid nanoparticle incorporated buccal films for oromucosal infections. Int J Pharm. 2024 Nov 15;665:124688. doi: 10.1016/j.ijpharm.2024.124688. Epub 2024 Sep 16. PMID: 39293576. 6: Fang Y, Clarke LG, Smith BJ, Shah S. Incidence of serotonin syndrome in patients receiving tedizolid and concomitant serotonergic agents. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0087024. doi: 10.1128/aac.00870-24. Epub 2024 Sep 5. PMID: 39235251; PMCID: PMC11459941. 7: Johnson TM, Rivera CG, Lee G, Zeuli JD. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2024 Jul 27;37:100470. doi: 10.1016/j.jctube.2024.100470. PMID: 39188351; PMCID: PMC11345926. 8: Chen RH, Burke A, Cho JG, Alffenaar JW, Davies Forsman L. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? Pharmaceutics. 2024 Jun 17;16(6):818. doi: 10.3390/pharmaceutics16060818. PMID: 38931939; PMCID: PMC11207443. 9: Zhou M, Liu ZL, Liu JY, Wang XB. Tedizolid phosphate alleviates DSS-induced ulcerative colitis by inhibiting senescence of cell and colon tissue through activating AMPK signaling pathway. Int Immunopharmacol. 2024 Jun 30;135:112286. doi: 10.1016/j.intimp.2024.112286. Epub 2024 May 21. PMID: 38776849. 10: Hou J, Xu Q, Zhou L, Chai J, Lin L, Ma C, Zhu Y, Zhang W. Identification of an Enterococcus faecium strain isolated from raw bovine milk co-harbouring the oxazolidinone resistance genes optrA and poxtA in China. Vet Microbiol. 2024 Jun;293:110103. doi: 10.1016/j.vetmic.2024.110103. Epub 2024 May 3. PMID: 38718528. 11: Kirkegaard C, Parramón-Teixidó CJ, Morales-Comas C, Clemente Bautista S, Rivero Deniz J, Fernández-Hidalgo N. Use of oxazolidinones (linezolid or tedizolid) for the treatment of breast infections. A case series from a tertiary referral hospital. Infection. 2024 Aug;52(4):1585-1593. doi: 10.1007/s15010-024-02269-y. Epub 2024 May 1. PMID: 38691231. 12: Yao Z, Xiao Y, Li W, Kong S, Tu H, Guo S, Liu Z, Ma L, Qiao R, Wang S, Chang M, Zhao X, Zhang Y, Xu L, Sun D, Fu X. FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect. J Assoc Res Otolaryngol. 2024 Jun;25(3):259-275. doi: 10.1007/s10162-024-00945-2. Epub 2024 Apr 15. PMID: 38622383; PMCID: PMC11150367. 13: Valentin B, Tchaparian M, Daran L, Fievet C, Odou P, Loiez C, Migaud H, Décaudin B, Senneville E. Kératodermie aquagénique palmaire secondaire au traitement d’une ostéite chronique par tédizolide : à propos d’un cas [Palmar aquagenic keratoderma secondary to treatment of chronic osteitis with tedizolide: A case report]. Therapie. 2024 Sep-Oct;79(5):614-615. French. doi: 10.1016/j.therap.2024.03.003. Epub 2024 Apr 2. PMID: 38599996. 14: Toyokawa M, Ohana N, Tanno D, Imai M, Takano Y, Ohashi K, Yamashita T, Saito K, Takahashi H, Shimura H. In vitro activity of tedizolid against 43 species of Nocardia species. Sci Rep. 2024 Mar 4;14(1):5342. doi: 10.1038/s41598-024-55916-7. PMID: 38438563; PMCID: PMC10912709. 15: Tebano G, Zaghi I, Baldasso F, Calgarini C, Capozzi R, Salvadori C, Cricca M, Cristini F. Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician? Pathogens. 2024 Jan 19;13(1):88. doi: 10.3390/pathogens13010088. PMID: 38276161; PMCID: PMC10819222. 16: Nau R, Seele J, Eiffert H. New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections. Antibiotics (Basel). 2024 Jan 7;13(1):58. doi: 10.3390/antibiotics13010058. PMID: 38247617; PMCID: PMC10812395. 17: Stellern JJ, Plaisted J, Welles C. Disseminated nocardiosis with persistent neurological disease. BMJ Case Rep. 2024 Jan 9;17(1):e257935. doi: 10.1136/bcr-2023-257935. PMID: 38195189; PMCID: PMC10806866. 18: Yokota K, Kawakami K. Efficacy and side-effect profile of tedizolid in the treatment of streptococcal toxic shock syndrome due to clindamycin-resistant Streptococcus pyogenes: A case report. J Infect Chemother. 2024 Aug;30(8):785-788. doi: 10.1016/j.jiac.2024.01.002. Epub 2024 Jan 6. PMID: 38185364. 19: Staudacher M, Hotz JF, Kriz R, Schefberger K, Schneider L, Spettel K, Starzengruber P, Hagemann JB, Leutzendorff A, Burgmann H, Lagler H. Differences in oxazolidinone resistance mechanisms and small colony variants emergence of Staphylococcus aureus induced in an in vitro resistance development model. Emerg Microbes Infect. 2024 Dec;13(1):2292077. doi: 10.1080/22221751.2023.2292077. Epub 2024 Feb 6. PMID: 38055244; PMCID: PMC10849000. 20: Jung E, Gademann K. Clinically Approved Antibiotics from 2010 to 2022. Chimia (Aarau). 2023 Apr 26;77(4):230-234. doi: 10.2533/chimia.2023.230. PMID: 38047802.

View History

Rubomycin H

Rubomycin H